藥碼
VEK02
藥名
Remdesivir 針 100 mg
英文商品名
Veklury 瑞德西韋 針 100 mg
中文商品名
韋如意(瑞德西韋)凍晶注射劑 100毫克
螢幕名
Remdesivir 瑞德西韋 針 100 mg
劑型
Inj
規格
成分
藥理分類
健保碼
ATC碼
藥品圖片
外觀圖片
適應症
【藥品庫存】
瑞德西韋本院備有庫存,請下載檢核表填寫後,提交給感染控制部,經確認無誤後,藥劑部將開檔供醫師醫囑。

 

Adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization.
藥理
Antiviral Agent. A SARS-CoV-2 nucleotide analog RNA polymerase inhibitor, , which is essential for viral replication.
藥動學
Protein binding: 88% to 93.6%
.Half-life elimination: ~1 hour
Excretion:
1. Urine: 10%
2. Feces: Not detected
禁忌症
Hypersensitivity to remdesivir or any component of the formulation.
懷孕分類

Dosage adjustment is not recommended for patients receiving treatment during pregnancy.<2024/7/8>

哺乳分類
It is not known if remdesivir is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk and benefits.
副作用
Skin rash, nausea, prolonged prothrombin time, increased serum ALT and AST, hypersensitivity reaction, seizure
Postmarketing: Bradycardia, cardiac failure, hypotension, severe bradycardia
劑量和給藥方法

Remdesivir has been FDA-approved for treatment of COVID-19 in hospitalized patients. However, US guideline recommendations on the role of remdesivir vary, and the World Health Organization recommends against the use of remdesivir in hospitalized patients, regardless of disease severity.

  • In patients over 28 days old and weigh at least 3 kg: 200 mg as a single dose on day 1, followed by 100 mg once daily infused over 30 to 120 minutes. Generally 5 days or until hospital discharge, but may extend to up to 10 days in certain patients (eg, patients requiring invasive mechanical ventilation and/or ECMO)<2024/7/8>

  • Geriatric: No dosage adjustment is required in patients over the age of 65 years.
小兒調整劑量
COVID-19, hospitalized patients:
Infants and Children <12 years
3.5 to <40 kg: Lyophilized powder only: IV: Loading dose: 5 mg/kg/dose on day 1, followed by 2.5 mg/kg/dose once daily.
≥40 kg: Lyophilized powder only: IV: Loading dose: 200 mg on day 1, followed by 100 mg once daily.
Children 12 years and Adolescents
<40 kg: Lyophilized powder only: IV: Loading dose: 5 mg/kg/dose on day 1, followed by 2.5 mg/kg/dose once daily.
≥40 kg: Injection solution or lyophilized powder: IV: Loading dose: 200 mg on day 1, followed by 100 mg once daily.
Duration:
Duration is generally 5 days or until hospital discharge, whichever is first, but may extend up to 10 days in certain hospitalized patients .
腎功能調整劑量

Dosage adjustment is not recommended (including for patients receiving dialysis).
The timing of dialysis does not need to be considered.<2024/7/8>

肝功能調整劑量

Dosage adjustment is not recommended.<2024/7/8>

安定性
VEKLURY contains no preservative.
藥袋資訊
臨床用途
重度新型冠狀病毒感染病人
主要副作用
發燒、噁心、嘔吐、皮疹、發汗、注射部位疼痛、肝腎功能異常
泡製方法
儲存方式
請置於 15-30℃ 乾燥處儲存
注意事項
其他說明
藥局 Z14 | 藥庫 注B11
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
0
自費價
0
仿單
資料庫
健保給付規定